Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Minimum commitment: 5 monthly sessions
Bespreek het dan altijd met je huisarts
In developing regions, this financial barrier is even more pronounced, slowing market penetration despite growing obesity prevalence While efforts are underway to improve affordabilityincluding the introduction of generic formulations and price negotiations in certain marketsthe perception of GLP-1 therapies as premium, high-cost treatments can deter both patients and providers from widespread adoption Overcoming these challenges through the development of cost-effective alternatives, enhanced insurance support, and patient assistance programs will be vital for ensuring sustained and inclusive market growth in the GLP-1 receptor agonists obesity drugs market GLP-1 Receptor Agonists Obesity Drugs Market Scope The market is segmented on the basis of drug type, route of administration, application, and distribution channel
Wegovy and Zepbound are now fully FDA approved for chronic weight management, regardless of diabetes status, as long as you meet the BMI or health condition criteria
It is not approved by any regulatory agency worldwide as of mid-2026
US$ 21.83
US$ 24.15
US$ 21.38
US$ 20.76
